This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
1 Citations 7 Q&As
1 Citations 9 Q&As
Facts about Interleukin-6 receptor subunit beta.
Binding of IL6 to IL6R induces IL6ST homodimerization and formation of a high-affinity receptor complex, which activates Janus kinases (PubMed:2261637). This causes phosphorylation of IL6ST tyrosine residues which in turn activates STAT3 (PubMed:19915009, PubMed:23294003).
Human | |
---|---|
Gene Name: | IL6ST |
Uniprot: | P40189 |
Entrez: | 3572 |
Belongs to: |
---|
type I cytokine receptor family |
CD130 antigen; CD130; CDw130; DKFZp564F053; gp130 of the rheumatoid arthritis antigenic peptide-bearing soluble form; gp130; IL-6 receptor subunit beta; IL-6R subunit beta; IL-6RB; IL-6R-beta; IL6ST; interleukin 6 signal transducer (gp130, oncostatin M receptor); interleukin receptor beta chain; interleukin-6 receptor subunit beta; Interleukin-6 signal transducer; Membrane glycoprotein 130; membrane glycoprotein gp130; Oncostatin-M receptor subunit alpha
Mass (kDA):
103.537 kDA
Human | |
---|---|
Location: | 5q11.2 |
Sequence: | 5; NC_000005.10 (55935095..55994963, complement) |
Found in all the tissues and cell lines examined (PubMed:2261637). Expression not restricted to IL6 responsive cells (PubMed:2261637). Expressed in blood serum (at protein level) (PubMed:24629561).
[Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Secreted.
If you're interested in learning more about Boster Bio's IL6ST Marker, you've come to the right place. We have compiled a list of the most important considerations when using this biomarker to aid your experiments. This article will detail the mapping of this biomarker on chromosome7p15 as well as how it was validated via WB and IHC.
The IL6ST Marker is useful in cancer immunotherapy to help stratify patients according their response to endocrine therapies. The predictive value of IL6ST has been demonstrated and can be used for guidance in choosing endocrine or chemotherapy therapy. Pretreatment levels IL6ST have been shown as a reliable predictor of response to AIs. The main classifier in the EER4 model has been updated to include IL6ST. These revised tools have demonstrated high accuracy and robustness across various validation cohorts and can easily be implemented in a local laboratory.
The 42GC study utilized a completely different approach. The team used biomarkers that monitor ER signalling to identify 8 cancer-related genes and biomarkers to analyze the data. They found that higher expression of IL6ST is associated with a better prognosis and a lower risk of distant recurrence. Although this research was preliminary, it does show the possibility of a clinical benefit from IL6ST in treating cancer.
While IL6ST may not be an approved cancer immunotherapy drug yet, it is a promising biomarker for patients suffering from ER+ breast cancer. There is a clear correlation between IL6 cytokines and oestrogen signalling. Further, IL6ST is an excellent surrogate marker for active oestrogen signalling and responsiveness to ET. This marker may also help identify breast lesions expressing active ER-dependent signals.
The IL6ST marker also predicts the failure of chemotherapy. Combining with the IRSN23 signature, IL6ST has been shown to predict nonpCR/ER+ BC. In ET, higher IL6ST expression was linked to lower EP scores as well as a lower response rate to NAC. The IL6ST marker should also be used for both types of cancer to determine the best treatment regimen.
The IL6ST gene can be found on chromosome 7p15. Sehgal and coworkers assigned the IL6 genetic code to chromosome 7.21-p15 in 1988. Another study mapped the IL6 gene to chromosome 7p15 by Bowcock and Sutherland. Their results confirmed their findings. A subsequent study in mice identified a novel IL6 gene on chromosome 7p15 and mapped it to the IL6 gene.
Polymorphisms are found at five-prime positions in the IL6 genes. The -174C allele is associated lower levels of IL6 production, while the G allele is associated higher levels of IL6 production. The G allele has been linked to lipid abnormalities. The immune system is a vital part of the IL6 genes, and overexpression has been associated several diseases including juvenile rheumatoidarthritis.
IL6ST was identified as a new predictor of breast cancer based on 10 independent studies. It was also associated ER status, age, and other factors. It was also associated with ER, HER2 or TNBC status. ANKRD30A expression was also associated with IL6ST. IL6ST plays a critical role in the ER+ pathway.
Digital droplet PCR validated the IL6ST marker. To confirm the differential expression of these marker markers, the study was performed with TNBC and non TNBC samples. The results were significant for each of the four genes tested, with ANKRD30A being the only one that was not detectable in the samples. These markers will need to be validated on IHC. Although IL6ST is a promising candidate for assessing TNBC-related risk, it is still a work product.
IL6ST acts as a signal transducer and is involved with cellular processes connected to BC hallmarks. This protein is expressed more in BC infiltrating nosdes than in benign lesion. IL6ST expression directly correlates with IL6 activation. This article reviews recent findings and discusses how these results can be used in clinical practice. The validation results of the IL6ST Marker will be used to guide the development and implementation of personalized treatments for BC residents.
The 42GC team used a unique approach for evaluating the relationship between IL6ST levels and distant recurrence. They assessed the clinical characteristics of participants, including tumour size and lymphode status, and evaluated the IL6ST-based EPclin assays. Their results confirmed that IL6ST is capable of predicting distant recurrence.
The researchers found that IL6ST was a significant predictor in late recurrence for patients who received ERBC. It has been proven that patients with higher levels of IL6ST expression respond less to a particular chemotherapy regimen. As a result, patients with higher levels of IL6ST expressed more aggressive treatments, such as chemotherapy.
The results of the validation study indicate that the IL6ST Marker has great promise as a disease biomarker for ER-positive breast cancer. The correlation between IL6 cytokines (like IL6) and oestrogen relating signalling is well understood. IL6ST may be an effective surrogate marker to detect ET-responsiveness or active oestrogen signling. The IL6STMarker may even be able to identify breast lesions exhibiting active ER-dependent signalling.
PMID: 2261637 by Hibi M., et al. Molecular cloning and expression of an IL-6 signal transducer, gp130.
PMID: 10880057 by Tanaka M., et al. Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis.
*More publications can be found for each product on its corresponding product page